More than 100 next generation RNA therapeutics and vaccines are being developed to offer an advanced, low-dose form of treatment, targeting a wide range of therapeutic indications

 

The traditional RNA-based therapies are known to be associated with various stability and delivery-related challenges. This has prompted industry stakeholders to modify such therapies to develop next generation therapies with enhanced stability and self-replicating capability. Further, the development of novel technologies for the development and delivery of such therapies has escalated the interest of industry stakeholders in enhanced and modified RNA-based therapies. The next generation RNA therapies domain is anticipated to evolve rapidly to become the next big therapeutic segment in the coming decade.

 

§  The financial opportunity associated with RNA Therapeutics and RNA Vaccines Market has been analyzed across the following segments:

§  Type of Modality

§  Therapeutics

§  Vaccines

 

§  Type of Molecule

§  Replicating RNA (repRNA)

§  Self amplifying RNA (saRNA)

§  Self activating RNA (sacRNA)

§  Self activating mRNA (sa-mRNA)

§  Transfer RNA (tRNA)

 

§   Therapeutic Area

§  Infectious Diseases

§  Oncological Disorders

§  Pulmonary Disorders

 

§  Route of Administration

§  Intradermal

§  Intramuscular

§  Intravenous

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia-Pacific

 

§  Leading Industry Players

§  Alphavax

§  Company 1

§  Company 2

§  Company 3

 

The RNA Therapeutics and RNA Vaccines Market, 2023-2035 report features the following companies, which we identified to be key players in this domain:

§  Alphavax

§  Arcturus Therapeutics

§  Atyr Pharma

§  Gritstone Bio

§  HDT Bio

§  MiNA Therapeutics

§  VLP Therapeutics

 

Table of Contents

 

1.       PREFACE

 

2.       RESEARCH METHODOLOGY

 

3.       ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

 

4.       EXECUTIVE SUMMARY

 

5.       INTRODUCTION

 

6.       MARKET LANDSCAPE

 

7.       TECHNOLOGY LANDSCAPE

 

8.       DRUG PROFILES

 

9.       CLINICAL TRIAL ANALYSIS

 

10.     PATENT ANALYSIS

 

11.     PARTNERSHIPS AND COLLABORATIONS

 

12.     FUNDING AND INVESTMENT ANALYSIS

 

13.     BIG PHARMA INITIATIVES

 

14.     OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, 2023-2035

 

15.     OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MODALITY

 

16.     OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY TYPE OF MOLECULE

 

17.     OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY THERAPEUTIC AREA

 

18.     OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY ROUTE OF ADMINISTRATION

 

19.     OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY KEY GEOGRAPHICAL REGIONS

 

20.     OVERALL RNA THERAPEUTICS AND RNA VACCINES MARKET, BY LEADING PLAYERS

 

21.     CONCLUSION

 

22.     APPENDIX 1: TABULATED DATA

         

23.     APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To view more details on this report, click on the link

https://www.rootsanalysis.com/reports/rna-therapeutics-market.html

 

News article

Antibody Drug Conjugate Market

 

Learn from experts:  do you know about these emerging industry trends?

Transformation of Biopharmaceuticals Manufacturing Through Single-use Bioreactors

Liposome: A Novel Drug Delivery System

 

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

 

Contact:

Ben Johnson

+1 (415) 800 3415

Ben.johnson@rootsanalysis.com